All In Biotech

Drug Trial Radar · NCT00349466

Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca

A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Keratoconjunctivitis Sicca

Last checked: Nov 20, 2026Latest source record: May 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Jan 2007

Primary completion

May 2009

Study completion May 2009

Sponsor

Lead sponsor
Can-Fite BioPharmaIndustry
Sponsor type
Industry
First posted
Jul 7, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS). Patients will be randomized to receive either CF101 1 mg or matching placebo, given orally every 12 hours (q12h) for 12 weeks. A Screening Period of up to 4 weeks that includes a 2-week run-in period will precede a 12-week treatment period, followed by a 2-week follow-up period.

Conditions

  • Keratoconjunctivitis Sicca

Interventions

  • CF101Drug

    Orally CF101 1mg

  • PlaceboDrug

    Orally matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Schirmer Test (ST) Score in MillimetersTime frame: 12 weeks
  2. Change From Baseline to Week 12 in Tear Break-Up Time (BUT) in SecondsTime frame: 12 weeks
  3. Number of Subjects With >25% Improvement in Fluorescein Staining of the Cornea (FS) at Week 12Time frame: 12 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Meir Hospital

    Kfar Saba, Israel

  • Sheba Medical Center

    Tel HaShomer, Israel

  • Assaf Harofeh Medical Center

    Tsrifin, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.